#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	787	5784	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2652	362.5	0	.	n	.	0	G426C	SNP	426	426	G	883	883	G	519	G	310	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	787	5784	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2652	362.5	0	.	n	.	0	C1450T	SNP	1450	1450	C	1907	1907	T	522	T	292	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	787	5784	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2652	362.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1641	1641	C	588	C	332	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10464	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3455	499.1	0	.	n	.	0	A9G	SNP	9	9	A	281	281	G	521	G	309	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10464	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3455	499.1	0	.	n	.	0	T695C	SNP	695	695	T	967	967	C	589	C	325	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10464	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3455	499.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2243	2243	C	503	C,G	293,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10464	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3455	499.1	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2869	2869	T	474	T,C	270,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10464	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3455	499.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2317	2317	A	512	A	300	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	408	folP	855	855	99.77	folP.l6.c4.ctg.1	1407	49.5	1	SNP	p	R229S	1	.	.	685	687	AGC	981	983	AGC	82;82;81	A;G;C	49;49;48	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1116	gyrA	2751	2751	99.78	gyrA.l6.c4.ctg.1	3446	55.1	0	.	p	.	0	T243I	NONSYN	727	729	ACA	967	969	ATA	85;83;67	A;T;A	49;46;40	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1116	gyrA	2751	2751	99.78	gyrA.l6.c4.ctg.1	3446	55.1	0	.	p	.	0	M250I	NONSYN	748	750	ATG	988	990	ATA	65;65;65	A;T;A	38;36;39	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1116	gyrA	2751	2751	99.78	gyrA.l6.c4.ctg.1	3446	55.1	1	SNP	p	S91F	0	.	.	271	273	TCC	511	513	TCC	82;82;82	T;C;C	43;43;42	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1116	gyrA	2751	2751	99.78	gyrA.l6.c4.ctg.1	3446	55.1	1	SNP	p	D95G	0	.	.	283	285	GAC	523	525	GAC	91;91;91	G;A;C	48;47;49	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1116	gyrA	2751	2751	99.78	gyrA.l6.c4.ctg.1	3446	55.1	1	SNP	p	D95N	0	.	.	283	285	GAC	523	525	GAC	91;91;91	G;A;C	48;47;49	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	531	280	mtrR	633	633	99.69	mtrR.l15.c4.ctg.1	1366	36.8	0	.	p	.	0	P191fs	FSHIFT	571	571	C	1025	1025	C	56	C	33	.	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	531	280	mtrR	633	633	99.69	mtrR.l15.c4.ctg.1	1366	36.8	1	SNP	p	G45D	0	.	.	133	135	GGC	586	588	GGC	72;74;74	G;G;C	41;43;42	mtrR.WHO_F_01564:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	188	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	871	35.6	0	.	n	.	0	.206T	INS	206	206	T	517	517	T	71	T	44	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	924	parC	2304	2304	99.74	parC.l6.c4.ctg.1	2699	58.0	0	.	p	.	0	V421A	NONSYN	1261	1263	GTC	1482	1484	GCC	61;61;57	G;C;C	36;36;32	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	924	parC	2304	2304	99.74	parC.l6.c4.ctg.1	2699	58.0	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1524	1526	GCA	59;59;60	G;C;A	34;32;32	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	924	parC	2304	2304	99.74	parC.l6.c4.ctg.1	2699	58.0	1	SNP	p	D86N	0	.	.	256	258	GAC	477	479	GAC	74;74;74	G;A,C;C	50;46,1;48	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	924	parC	2304	2304	99.74	parC.l6.c4.ctg.1	2699	58.0	1	SNP	p	S87I	0	.	.	259	261	AGT	480	482	AGT	74;75;76	A,C;G;T	48,1;48;48	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	924	parC	2304	2304	99.74	parC.l6.c4.ctg.1	2699	58.0	1	SNP	p	S87R	0	.	.	259	261	AGT	480	482	AGT	74;75;76	A,C;G;T	48,1;48;48	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	924	parC	2304	2304	99.74	parC.l6.c4.ctg.1	2699	58.0	1	SNP	p	S87W	0	.	.	259	261	AGT	480	482	AGT	74;75;76	A,C;G;T	48,1;48;48	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	924	parC	2304	2304	99.74	parC.l6.c4.ctg.1	2699	58.0	1	SNP	p	S88P	0	.	.	262	264	TCC	483	485	TCC	76;76;76	T;C,T;C	51;48,1;52	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_W_01411c	parE.WHO_W_01411c	1	1	27	868	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2433	59.5	1	SNP	p	G410V	0	.	.	1228	1230	GGT	1499	1501	GGT	52;52;52	G;G;T	32;34;29	parE.WHO_W_01411c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	1054	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2103	79.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1109	1111	GCA	100;100;100	G;C;A	58;58;59	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1054	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2103	79.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1112	1114	ATC	100;98;97	A;T;C	59;58;57	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1054	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2103	79.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1124	1126	GTG	97;97;97	G;T;G	57;54;54	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1054	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2103	79.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1124	1126	GTG	97;97;97	G;T;G	57;54;54	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1054	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2103	79.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1628	1630	ACC	74;75;71	A;C;C	44;44;43	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1054	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2103	79.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1682	1684	GCG	75;75;76	G;C;G	48;44;45	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1054	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2103	79.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1682	1684	GCG	75;75;76	G;C;G	48;44;45	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1054	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2103	79.9	1	SNP	p	G543S	0	.	.	1627	1629	GGT	1805	1807	GGT	85;85;84	G;G;T	48;49;48	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1054	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2103	79.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1814	1816	GGC	81;81;79	G;G;C	47;46;45	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1054	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2103	79.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1832	1834	CCG	73;71;69	C;C;G	37;41;38	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1710	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3118	85.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	552	porA	1146	1146	99.65	porA.l6.c4.ctg.1	2056	43.3	0	.	p	.	0	S22G	NONSYN	64	66	AGC	396	398	GGC	73;73;73	G;G;C	43;44;44	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	552	porA	1146	1146	99.65	porA.l6.c4.ctg.1	2056	43.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	578	578	C	36	C	20	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	T18M	NONSYN	52	54	ACG	504	506	ATG	52;50;54	A;T;G	32;30;32	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	E48G	NONSYN	142	144	GAA	594	596	GGA	67;67;67	G;G;A	37;38;38	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	V75I	NONSYN	223	225	GTT	675	677	ATT	60;60;60	A;T;T	35;34;35	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	T89S	NONSYN	265	267	ACC	717	719	AGC	47;47;43	A;G;C	29;30;27	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	V98I	NONSYN	292	294	GTC	744	746	ATC	41;41;41	A;T;C	27;25;25	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	.	MULTIPLE	358	359	AA	809	810	CG	31;31	C;G	20;19	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	.	MULTIPLE	361	362	GA	812	814	CAG	34;35;35	C;A;G	22;22;21	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	N122K	NONSYN	364	366	AAC	816	818	AAA	35;35;37	A;A;A	21;22;23	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	843	845	TAT	48;48;48	T;A;T	29;29;27	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	N134K	NONSYN	400	402	AAT	852	854	AAG	48;48;48	A;A;G,T	28;28;28,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	V135F	NONSYN	403	405	GTG	855	857	TTT	48;48;48	T;T;T	26;28;28	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	G140K	NONSYN	418	420	GGA	870	872	AAA	47;47;47	A;A;A	28;28;28	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	K143E	NONSYN	427	429	AAA	879	881	GAA	51;56;59	G;A;A	30;34;34	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	V151A	NONSYN	451	453	GTA	903	905	GCA	59;58;58	G;C;A	32;33;32	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	T213S	NONSYN	637	639	ACA	1089	1091	TCA	66;73;77	T;C;A	37;42;44	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1209	1211	CAA	61;61;61	C;A;A	36;36;37	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	.	INDELS	760	762	ACA	1213	1217	ATCAA	63;63;62;61;61	A;T;C;A;A	37;38;38;36;37	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	.	INDELS	763	764	TG	1220	1222	AGT	61;61;61	A;G;T,G	35;34;33,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1227	1229	GAT	63;63;63	G;A;T	37;38;38	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	T269S	NONSYN	805	807	ACC	1263	1265	AGC	71;71;72	A;G;C	40;41;41	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1335	1337	AGT	88;88;81	A;G;T	51;50;45	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1341	1343	GAC	91;91;92	G,A;A;C	51,2;50;52	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1344	1346	TAC	90;91;93	T,C;A;C	49,1;52;55	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	1	SNP	p	G120K	1	.	.	358	360	AAG	809	811	CGG	31;31;31	C;G;G	20;19;18	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	1	SNP	p	A121D	1	.	.	361	363	GAC	812	815	CGC	34;35;35	C;G;C	22;21;21	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	480	porB1b	1041	1041	96.37	porB1b.l6.c4.ctg.1	1743	47.3	1	SNP	p	D121N	0	.	.	361	363	GAC	812	815	CGC	34;35;35	C;G;C	22;21;21	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	40	porB3	990	217	94.47	porB3.l15.c4.ctg.2	235	4.5	0	.	p	.	0	T252S	NONSYN	754	756	ACC	47	49	AGC	6;6;6	A;G;C	3;3;3	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	40	porB3	990	217	94.47	porB3.l15.c4.ctg.2	235	4.5	0	.	p	.	0	L253V	NONSYN	757	759	TTG	50	52	GTG	6;6;6	G;T;G	3;3;3	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	40	porB3	990	217	94.47	porB3.l15.c4.ctg.2	235	4.5	0	.	p	.	0	S273T	NONSYN	817	819	TCG	110	112	ACT	2;2;2	A;C;T	1;1;1	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	40	porB3	990	217	94.47	porB3.l15.c4.ctg.2	235	4.5	0	.	p	.	0	D276S	NONSYN	826	828	GAT	119	121	AGT	2;2;2	A;G;T	1;1;1	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	40	porB3	990	217	94.47	porB3.l15.c4.ctg.2	235	4.5	0	.	p	.	0	K278D	NONSYN	832	834	AAA	125	127	GAC	2;2;2	G;A;C	1;1;1	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	40	porB3	990	217	94.47	porB3.l15.c4.ctg.2	235	4.5	0	.	p	.	0	R279Y	NONSYN	835	837	CGC	128	130	TAC	2;2;2	T;A;C	1;1;1	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	2746	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4633	98.9	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1846	1848	CAT	134;134;134	C;A;T	76;76;75	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	240	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1108	38.8	1	SNP	p	V57M	1	.	.	169	171	ATG	567	569	ATG	97;94;94	A;T;G	54;52;52	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
